Massey G V, Dunn N L, Heckel J L, Myer E C, Russell E C
Department of Pediatrics, Medical College of Virginia, Richmond.
Pediatr Neurol. 1994 Jul;11(1):59-61. doi: 10.1016/0887-8994(94)90093-0.
We describe a case of aplastic anemia in an 8-year-old girl which was diagnosed 8 months after initiation of ethosuximide as treatment for absence seizures. Blood counts had been previously monitored and were normal. The patient successfully underwent allogeneic bone marrow transplantation. Only 8 cases of ethosuximide-associated aplastic anemia have been reported, and in only one of these reports, was ethosuximide used as a single antiepileptic agent. This rare, but potentially fatal complication of ethosuximide raises the question of whether routine monitoring of blood counts during ethosuximide therapy is useful and should be undertaken.
我们描述了一名8岁女孩患再生障碍性贫血的病例，该病例在开始使用乙琥胺治疗失神发作8个月后被诊断出来。此前血细胞计数一直处于监测中且结果正常。该患者成功接受了异基因骨髓移植。据报道，乙琥胺相关的再生障碍性贫血病例仅有8例，其中仅有一篇报道将乙琥胺用作单一抗癫痫药物。乙琥胺这种罕见但可能致命的并发症引发了一个问题，即在乙琥胺治疗期间进行血常规的常规监测是否有用以及是否应该进行。
